The activity, safety, and evolving role of brigatinib in patients with <em>ALK</em>-rearranged non-small cell lung cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

Published:2017-04 Issue: Volume:Volume 10 Page:1983-1992
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Sabari Joshua K,Santini Fernando^ORCID,Schram Alison M,Bergagnini Isabella,Chen Ruqin,Mrad Chebli,Lai W Victoria,Arbour Kathryn C,Drilon Alexander

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

2. Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report;Case Reports in Oncology;2024-08-27

3. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies;Journal of Medicinal Chemistry;2024-08-15

4. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23

5. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy;Molecules;2024-03-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP